ReNerve Limited has secured market registration approval in Malaysia for its NervAlign® Nerve Cuff, marking another regulatory milestone in the Company’s Asia-Pacific expansion strategy. The approval adds to existing clearances in Hong Kong and Thailand and follows a positive assessment of ReNerve’s clinical evaluation data. With an established US commercial base and a growing portfolio of nerve repair and tissue products.

ReNerve Limited (ASX: RNV) listed on the ASX in July 2023, positioning itself as a commercial-stage medtech company aiming to transform nerve repair through innovative tissue-engineered solutions. Less than two years later, the company has demonstrated consistent momentum in bringing its products to market, establishing international distribution networks, and expanding its product pipeline.